Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Canthal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Canthal. Displaying page 1 of 1.
    EudraCT Number: 2010-021936-33 Sponsor Protocol Number: RD.03.SPR.40131 Start Date*: 2011-01-28
    Sponsor Name:Galderma R&D SNC
    Full Title: A multi-center randomized, double-blind, placebo controlled, parallel-group study of CD 07743 for the improvement of Lateral Canthal Lines (crow’s feet)
    Medical condition: Moderate to severe Lateral Canthal Lines
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001815-38 Sponsor Protocol Number: 191622-143 Start Date*: 2014-12-16
    Sponsor Name:Allergan Limited
    Full Title: Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canth...
    Medical condition: Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10048043 Wrinkling LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005279-10 Sponsor Protocol Number: MT10109L-002 Start Date*: 2019-09-24
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
    Medical condition: Lateral Canthal Lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-005302-38 Sponsor Protocol Number: MT10109L-006 Start Date*: 2019-12-18
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines Wi...
    Medical condition: Lateral Canthal Lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021271-83 Sponsor Protocol Number: 191622-104 Start Date*: 2011-04-27
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Extension Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Sub...
    Medical condition: Treatment of lateral canthal rhytides in the periorbital region (CFL)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10040954 Skin wrinkling LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005303-24 Sponsor Protocol Number: MT10109L-004 Start Date*: 2020-09-18
    Sponsor Name:Medytox Inc
    Full Title: A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines
    Medical condition: Glabellar Lines & Lateral Canthal Lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020827-28 Sponsor Protocol Number: 191622-098 Start Date*: 2011-06-10
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Single Treatment Cycle Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Lateral Can...
    Medical condition: Treatment of lateral canthal rhytides in the periorbital region (Crow's Feet Lines)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10040954 Skin wrinkling PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005301-21 Sponsor Protocol Number: MT10109L-005 Start Date*: 2019-06-21
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or ...
    Medical condition: Glabellar Lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020828-21 Sponsor Protocol Number: 191622-099 Start Date*: Information not available in EudraCT
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with...
    Medical condition: Treatment of lateral canthal rhytides in the periorbital region (CFL)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10040954 Skin wrinkling PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004113-13 Sponsor Protocol Number: M602011070 Start Date*: 2020-08-17
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the simultaneous treatment of ...
    Medical condition: Moderate to severe upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral canthal lines)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10048042 Wrinkles LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10052609 Glabellar frown lines LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10052611 Crow's feet LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10040954 Skin wrinkling PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004592-36 Sponsor Protocol Number: RD.03.SPR.29097 Start Date*: 2012-04-12
    Sponsor Name:Galderma R&D
    Full Title: Subjects’ satisfaction on pan facial aesthetic enhancement after treatment with Azzalure® and the Restylane® range
    Medical condition: Facial volume loss and dynamic wrinkles of the upper third of the face
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10040954 Skin wrinkling PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 16:48:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA